Claritev (NYSE:CTEV) SVP Tiffani Misencik Sells 5,812 Shares of Stock

Claritev (NYSE:CTEV) SVP Tiffani Misencik sold 5,812 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.81, for a total value of $138,383.72. Following the completion of the sale, the senior vice president directly owned 107,917 shares of the company’s stock, valued at $2,569,503.77. This trade represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tiffani Misencik also recently made the following trade(s):

• On Friday, August 14th, Tiffani Misencik sold 8,850 shares of Claritev stock. The stock was sold at an average price of $40.07, for a total value of $354,619.50.

Claritev Stock Performance

Shares of CTEV stock traded down $1.80 on Friday, hitting $22.06. 188,785 shares of the stock traded hands, compared to its average volume of 162,567. The firm’s 50-day moving average price is $31.85 and its two-hundred day moving average price is $27.59. The stock has a market capitalization of $373.92 million, a PE ratio of -1.30 and a beta of 0.93. Claritev has a twelve month low of $11.50 and a twelve month high of $73.68.

Claritev (NYSE:CTEV) last released its quarterly earnings data on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.10) by $5.51. The firm had revenue of $257.48 million for the quarter. On average, equities research analysts anticipate that Claritev will post -15.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Wall Street Zen upgraded Claritev from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research upgraded Claritev from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Citigroup reaffirmed a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Claritev in a research note on Monday, August 10th. Piper Sandler reiterated an “overweight” rating and set a $73.00 price target on shares of Claritev in a report on Wednesday, August 12th. Finally, Barclays reiterated an “overweight” rating and set a $40.00 price target (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $44.83.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Arini Captial Management Ltd acquired a new stake in shares of Claritev in the fourth quarter valued at $64,291,000. Public Investment Fund acquired a new position in Claritev in the 2nd quarter valued at about $43,703,438. RBF Capital LLC grew its position in Claritev by 0.8% in the 1st quarter. RBF Capital LLC now owns 135,314 shares of the company’s stock valued at $2,211,000 after acquiring an additional 1,127 shares in the last quarter. Bank of America Corp DE grew its position in Claritev by 146.6% in the 1st quarter. Bank of America Corp DE now owns 97,795 shares of the company’s stock valued at $1,598,000 after acquiring an additional 58,133 shares in the last quarter. Finally, FAS Wealth Partners Inc. increased its stake in Claritev by 49.5% during the first quarter. FAS Wealth Partners Inc. now owns 46,477 shares of the company’s stock worth $759,000 after purchasing an additional 15,380 shares during the period. 87.15% of the stock is currently owned by institutional investors and hedge funds.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.